Leadership

Dr. Chowdhury has served as CEO and chair of the board of Nemaura Medical Inc., since 2013. He has over 20 years experience in the Pharmaceutical and Medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents across over 15 technology platforms within the medical device and pharmaceutical sectors and has authored Textbook Chapters on Nano-biosciences for Wiley and Elsevier. Dr Chowdhury is a regular speaker at international conferences in this field, and serves on the Board of Medilink East Midlands, UK. He holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and Doctorate from the University of Oxford on nano-medicine and drug delivery.

Mr. Mclarney brings a wealth of experience within International Finance, Accounting, and Process Development & Control having been a Chartered Accountant since 1999. He has a strong track record of driving profitable growth across businesses encompassing ecommerce, retail, logistics, and supply chain operations at an international level. Mr. McIarney has held various Senior Finance & Operational roles, including most recently the position of Senior Director, International Finance at Lands’ End Inc. from January 2016 to May 2020 where he was responsible for the Finance and Operations teams across the European and Japanese business units. From February 2007 to September 2015, Mr. Mclarney worked for Office Depot in a range of increasingly senior roles culminating in the position of Senior Director of Finance for the largest business unit within the European group; during his time at Office Depot, Mr. Mclarney was also directly involved in the development and delivery of new service offerings into existing markets in addition to the acquisition integration of new geographical markets, ranging in size and scale from Sweden to India and China. Prior to this, he spent over 10 years in practice, the majority of which was with Ernst & Young LLP. Before his transition into Accountancy, Mr. McIarney studied Law and obtained his Legal Practice Certificate.

Mr. Avery brings over 30 years of senior experience in the healthcare industry with a focus on launching products, establishing distribution channels, and developing international relationships. Previously, Mr. Avery co-founded DiagnoSys Medical, a UK medical device distribution company. In this role, Mr. Avery recruited, trained, and launched a field-based sales team and was responsible for negotiating the sale of the business to Home Diagnostics. Subsequently, Mr. Avery served as European Director and UK Managing Director at Home Diagnostic Inc. During his tenure at Home Diagnostics, Mr. Avery launched the company’s glucose monitoring portfolio, Orbus Stents and Animas insulin pumps, into the UK and helped build the European distribution network. Following Home Diagnostics Inc., Mr. Avery served as European Director and UK Managing Director at Nipro Diagnostics, a company dedicated to helping people with diabetes manage their disease by providing blood glucose monitoring systems and other diabetes products. While at Nipro, he re-focused the organization, delivering a new strategic direction and leadership that increased market penetration. Additionally, Mr. Avery established and managed the sales operations for the organization within various regions and oversaw distributors within the EU and Africa.  Most recently, Mr. Avery served as Senior Vice President of Business Development at Dallas Burston Ethitronix (DBE), where he was heavily involved in establishing and overseeing the Collaboration Agreement with Nemaura to commercialize SugarBEAT® in Europe. Mr. Avery oversaw the pre-launch phase for the distribution of SugarBEAT®, cultivating relationships with suppliers and diabetes key opinion leaders.

Professor Karrar Khan has over 35 years’ experience of drug discovery, pharmaceutical development, registration and managing pharmaceutical scientists. His experience includes 20 years as Head of Pharmaceutical Development for Boots Pharmaceuticals and Knoll and two years as Director for OSI where he managed their pharmaceutical development, analytical operations and DMPK. His expertise range from development for phase 1 to phase 3- 4 and significant experience of bringing prescription and OTC products to market on a global level (and has contributed to the registration and launch of over 60 pharmaceutical products). He is a Qualified person under the EC quality assurance directive.

Dr. Schaebsdau has over 15 years of executive level experience in the CGM, Blood Glucose Monitoring (BGM) and insulin delivery industries, which started in 2004 during his tenure with Abbott Diabetes Care, where he was a member of the M&A and post-merger integration teams responsible for the acquisition of TheraSense and its FreeStyle Navigator CGM. From September 2016 until January 2019, he was the General Manager of Dexcom Germany, which during his leadership became the fastest growing organization in Dexcom’s history achieving triple digit revenue and new patient growth every year. Two generations of CGM, G5 and G6, were successfully launched and negotiations with public insurers completed, which resulted in full reimbursement for >85% of the German population. From 2009 until August 2015, at Roche Diabetes Care, he was Senior Vice-President, Head of Global Strategy and Business Development, completing several strategic acquisitions, partnerships and licensing deals. In September 2015, he founded his own firm as exclusive distributor in Europe, the Middle East and Africa for UniStrip^®, the world’s first generic blood glucose test strip. Since September 2015, he is a member of the Advisory Board of Peppermint Venture Partners. Dr. Schaebsdau studied Medicine at the University of Giessen and completed residencies in urology and surgery at the University of Chicago, University of Hannover and University of Freiburg. He is licensed to practice medicine in the U.S. and Germany. During his residency at the University of Hannover he conducted primary research in neurophysiology with a grant from the DFG (Deutsche Forschungsgemeinschaft) and completed his PhD. In 1993, he received an MBA from The Wharton School of the University of Pennsylvania.

David Scott is a trained chemist with over 35 years’ experience in the Pharmaceutical Industry spanning deal brokering, marketing, strategic planning, finance, business development and acquisitions. He is a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products, delivery systems and technologies. He has also provided licensing training for a number of multinational pharma companies and training organisations and has published widely, (he is the author of the best-selling report, “Scrip’s Practical Guide to Pharmaceutical Licensing”). David is also an accredited “Certified Licensing Professional”.